Mesoblast Limited
MEOBF
$1.55
-$0.04-2.52%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,526.81% | 1,526.81% | 458.55% | 458.55% | -6.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,526.81% | 1,526.81% | 458.55% | 458.55% | -6.85% |
| Cost of Revenue | 957.35% | 957.35% | 45.91% | 45.91% | -35.22% |
| Gross Profit | -25.66% | -25.66% | -10.57% | -10.57% | 56.77% |
| SG&A Expenses | 58.46% | 58.46% | 63.88% | 63.88% | 56.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -6,253.49% | -6,253.49% | 334.57% | 334.57% | 104.76% |
| Total Operating Expenses | 244.26% | 244.26% | 66.66% | 66.66% | -22.79% |
| Operating Income | -41.71% | -41.71% | -35.27% | -35.27% | 24.83% |
| Income Before Tax | 16.77% | 16.77% | 2.55% | 2.55% | -46.20% |
| Income Tax Expenses | 109.91% | 109.91% | 232.58% | 232.58% | 307.84% |
| Earnings from Continuing Operations | 16.21% | 16.21% | 2.18% | 2.18% | -47.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.21% | 16.21% | 2.18% | 2.18% | -47.31% |
| EBIT | -41.71% | -41.71% | -35.27% | -35.27% | 24.83% |
| EBITDA | -32.56% | -32.56% | -28.70% | -28.70% | 26.02% |
| EPS Basic | 26.19% | 26.19% | 15.48% | 15.48% | -12.90% |
| Normalized Basic EPS | 3.36% | 3.36% | 18.32% | 18.32% | -3.48% |
| EPS Diluted | 25.71% | 25.71% | 15.48% | 15.48% | -12.90% |
| Normalized Diluted EPS | 3.36% | 3.36% | 18.32% | 18.32% | -3.48% |
| Average Basic Shares Outstanding | 13.11% | 13.11% | 15.96% | 15.96% | 30.49% |
| Average Diluted Shares Outstanding | 13.11% | 13.11% | 15.96% | 15.96% | 30.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |